title: Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16)(q23;p13) chromosome translocation.
abstract: CBP, which is located on 16p13 and encodes a transcriptional adaptor/coactivator protein, has been shown to fuse by the t(8;16)(p11;p13) translocation to MOZ on 8p11 in acute myeloid leukemia. We found a t(11;16)(q23;p13) in a child with therapy-related chronic myelomonocytic leukemia. Subsequent reverse transcriptase-polymerase chain reaction and direct sequencing analyses revealed the MLL-CBP fusion transcript in CMML cells. Because 11q23 translocations involving MLL and t(8;16) involving MOZ and CBP have been reported in therapy-related leukemias, both the MLL and CBP genes may be targets for topoisomerase II inhibitors. Accordingly, we believe that most t(11;16)-associated leukemias may develop in patients who have been treated with cytotoxic chemotherapy for primary malignant diseases.
authors.affiliation: Third Clinical Department, Saitama Cancer Center Hospital, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Satake
authors.forename: Y
authors.initials: Y
authors.lastname: Ishida
authors.forename: Y
authors.initials: Y
authors.lastname: Otoh
authors.forename: S
authors.initials: S
authors.lastname: Hinohara
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.forename: A
authors.initials: A
authors.lastname: Sakashita
authors.forename: N
authors.initials: N
authors.lastname: Maseki
authors.forename: Y
authors.initials: Y
authors.lastname: Kaneko
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015139:Blotting, Southern; D050882:CREB-Binding Protein; D002648:Child; D002871:Chromosome Banding; D002880:Chromosomes, Human, Pair 11 / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D017931:DNA Primers; D004273:DNA, Neoplasm / Q000032:analysis; D004268:DNA-Binding Proteins / Q000235:genetics*; D015321:Gene Rearrangement; D011495:Histone-Lysine N-Methyltransferase; D006801:Humans; D015477:Leukemia, Myelomonocytic, Chronic / Q000139:chemically induced / Q000235:genetics*; D008297:Male; D051788:Myeloid-Lymphoid Leukemia Protein; D016609:Neoplasms, Second Primary / Q000235:genetics*; D009687:Nuclear Proteins / Q000235:genetics*; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000235:genetics; D011519:Proto-Oncogenes; D012194:RNA-Directed DNA Polymerase; D011995:Recombination, Genetic; D012074:Remission Induction; D017422:Sequence Analysis, DNA; D015534:Trans-Activators; D014157:Transcription Factors / Q000235:genetics*; D014178:Translocation, Genetic
chemical_list: D017931:DNA Primers; D004273:DNA, Neoplasm; D004268:DNA-Binding Proteins; C497422:KMT2A protein, human; D009687:Nuclear Proteins; D015534:Trans-Activators; D014157:Transcription Factors; D051788:Myeloid-Lymphoid Leukemia Protein; D011495:Histone-Lysine N-Methyltransferase; D050882:CREB-Binding Protein; C494363:CREBBP protein, human; D012194:RNA-Directed DNA Polymerase